Differing Expression of Cytokines and Tumor Markers in Combined Pulmonary Fibrosis and Emphysema Compared to Emphysema and Pulmonary Fibrosis

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 14, Issue 2, 2017, Pages 245-250

  Xu, Ling ^a   Bian, Wei ^a   Gu, Xiao Hua ^a   Shen, Ce ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Cytokeratin 19 fragment; Krebs Von Den Lungen 6; matrix metalloproteinase 9; telomerase; transforming growth factor 1; vascular endothelial growth factor

Indexed keywords

CYTOKERATIN 19 FRAGMENT; CYTOKINE; GELATINASE B; KREBS VON DEN LUNGEN 6; SQUAMOUS CELL CARCINOMA ANTIGEN; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIGEN CYFRA21.1; CYTOKERATIN 19; MMP9 PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; MUCIN 1; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TIMP1 PROTEIN, HUMAN; TUMOR ANTIGEN; VASCULOTROPIN A;

AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG EMPHYSEMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; BLOOD; COMPLICATION;

AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; KERATIN-19; MALE; MATRIX METALLOPROTEINASE 9; MUCIN-1; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; SERPINS; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85010700261     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412555.2017.1278753     Document Type: Article

References (49)

1. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema:the value of high resolution computed tomography in assessment. Respir. Med. 1990; 84(5):365–9.
2. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema:a distinct underrecognised entity. Eur. Respir. J. 2005; 26(4):586–93.
3. Kim JY, Choeng HC, Ahn C, Cho SH. Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis. Yonsei Med. J. 2009; 50(1):68–77.
4. Gansner JM, Rosas IO. Telomeres in lung disease. Transl. Res. 2013; 162(6):343–52.
5. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B, et al. Telomerase activity is required for bleomycin induced pulmonary fibrosis in mice. J. Clin. Invest. 2007; 117(12):3800–9.
6. Le Saux CJ, Davy P, Brampton C, Ahuja SS, Fauce S, Shivshankar P, et al. A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS One 2013; 8(3):e58423.
7. Königshoff M, Kneidinger N, Eickelberg O. TGF-β signalling in COPD:deciphering genetic and cellular susceptibilities for future therapeutic regimens. Swiss Med. Wkly. 2009; 139(39–40):554–63.
8. Lee CG, Cho S, Homer RJ, Elias JA. Genetic control of transforming growth factor-β1-induced emphysema and fibrosis in the murine lung. Proc. Am. Thorac. Soc. 2006; 3(6):476–7.
9. Kanazawa H, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin in emphysema. Eur. Respir. J. 2003; 22(4):609–12.
10. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 2001; 163(3 Pt 1):737–44.
11. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int. Immunopharmacol. 2009; 9(1):70–9.
12. Stockmann C, Kerdiles Y, Nomaksteinsky M, Weidemann A, Takeda N, Doedens A, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc. Natl. Acad. Sci. U S A. 2010; 107(9):4329–34.
13. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96(1):68–73.
14. Iyonaga K, Miyajima M, Suga M, Saita N, Ando M. Alterations in cytokeratin expression by the alveolar lining epithelial cells in lung tissues from patients with idiopathic pulmonary fibrosis. J. Pathol. 1997; 182(2):217–24.
15. Calabrese F, Lunardi F, Giacometti C, Marulli G, Gnoato M, Pontisso P, et al. Overexpression of squamous cell carcinoma antigen in idiopathic pulmonary fibrosis:clinicopathological correlations. Thorax 2008; 63(9):795–802.
16. Kobayashi J, Kitamura S. KL-6:a serum marker for interstitial pneumonia. Chest 1995; 108(2):311–5.
17. Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11(2):164–8.
18. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, et al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur. Respir. J. 1999; 14(3):574–8.
19. Xu L, Bian W, Gu J, Yang DR, Rong ZH, Shen C. Clinical significance of tumour markers in idiopathic pulmonary fibrosis. J. Clin. Pulm. Med. 2013; 18(10):1865–7. [Article in Chinese].
20. Ito M, Hanaoka M, Droma Y, Hatayama O, Sato E, Katsuyama Y, et al. The association of transforming growth factor beta 1 gene polymorphisms with the emphysema phenotype of COPD in Japanese. Intern. Med. 2008; 47(15):1387–94.
21. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183(6):788–824.
22. Kratzer A, Salys J, Nold-Petry C, Cool C, Zamora M, Bowler R, et al. Role of IL-18 in second-hand smoke–induced emphysema. Am. J. Respir. Cell Mol. Biol. 2013; 48(6):725–32.
23. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 2000; 106(11):1311–9.
24. Takahashi Y, Izumi Y, Kohno M, Ikeda E, Nomori H. Airway administration of vascular endothelial growth factor siRNAs induces transient airspace enlargement in mice. Int. J. Med. Sci. 2013; 10(12):1702–14.
25. Mura M, Binnie M, Han B, Li C, Andrade CF, Shiozaki A, et al. Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. Am. J. Pathol. 2010; 176(4):1725–34.
26. Chen YB, Lan YW, Chen LG, Huang TT, Choo KB, Cheng WT, et al. Mesenchymal stem cell-based HSP70 promoter-driven VEGFA induction by resveratrol alleviates elastase-induced emphysema in a mouse model. Cell Stress Chaperones. 2015; 20(6):979–89.
27. Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A, et al. Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit. Care Med. 2007; 35(9):2164–70.
28. Hamada N, Kuwano K, Yamada M, Hagimoto N, Hiasa K, Egashira K, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J. Immunol. 2005; 175(2):1224–31.
29. Ando M, Miyazaki E, Ito T, Hiroshige S, Nureki SI, Ueno T, et al. Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung 2010; 188(3):247–52.
30. Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J. Clin. Invest. 2009; 119(5):1298–311.
31. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur. Respir. J. 2003; 22(1):69–76.
32. Xu L, Yang D, Zhu S, Gu J, Ding F, Bian W, et al. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. Exp. Lung Res. 2013; 39(6):241–8.
33. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. 1997; 100(4):768–76.
34. Kamio K, Ishii T, Motegi T, Hattori K, Kusunoki Y, Azuma A, et al. Decreased serum transforming growth factor-b1 concentration with aging is associated with the severity of emphysema in chronic obstructive pulmonary disease. Geriatr. Gerontol. Int. 2013; 13(4):1069–75.
35. Horowitz JC, Martinez FJ, Thannickal VJ. Mesenchymal cell fate and phenotypes in the pathogenesis of emphysema. COPD 2009; 6(3):201–10.
36. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes MMP12-dependent emphysema. Nature 2003; 422(6928):169–73.
37. Samukawa T, Hamada T, Uto H, Yanagi M, Tsukuya G, Nosaki T, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm. Med. 2012; 12:55.
38. Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, et al. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir. Med. 2014; 108(7):1031–9.
39. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem. Biophys. Res. Commun. 2005; 338(4):1845–52.
40. Xu L, Yan DR, Zhu SL, Gu J, Bian W, Rong ZH, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation. Eur. Rev. Med. Pharmacol. Sci. 2013; 17(22):3073–7.
41. Kokuho N, Ishii T, Kamio K, Hayashi H, Kurahara M, Hattori K, et al. Diagnostic values for club cell secretory protein (CC16) in serum of patients of combined pulmonary fibrosis and emphysema. COPD 2015; 12(4):347–54.
42. Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 2006; 61(12):1037–42.
43. D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, et al. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. PLoS One 2013; 8(2):e56352.
44. Foronjy R, Nkyimbeng T, Wallace A, Thankachen J, Okada Y, Lemaitre V, et al. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am. J. Physiol. Lung Cell Mol. Physiol. 2008; 294(6):L1149–57.
45. Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, et al. The role of matrix metalloproteinase-9 in cigarette smoke–induced emphysema. Am. J. Respir. Crit. Care Med. 2011; 183(7):876–84.
46. Cabrera S, Gaxiola M, Arreola JL, Ramírez R, Jara P, D'Armiento J, et al. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int. J. Biochem. Cell Biol. 2007; 39(12):2324–38.
47. Jin X, Dai H, Ding K, Xu X, Pang B, Wang C. Rapamycin attenuates bleomycin-induced pulmonary fibrosis in rats and the expression of metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in lung tissue. Chin. Med. J. 2014; 127(7):1304–9.
48. Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, Gorgy AI, et al. Telomere length is a determinant of emphysema susceptibility. Am. J. Respir. Crit. Care Med. 2011; 184(8):904–12.
49. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5(5):e10680.